This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin .alpha..sub.v.beta..sub.3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of .alpha..sub.v.beta..sub.3-mediated disorders, such as restenosis, in human patients.